REQUEST A DEMO
Total
USD $0.00
Search more companies

Pt Dwi Tunggal Pharma Mandiri (Indonesia)

Main Activities: Drugs and Druggists' Sundries Merchant Wholesalers
Full name: Pt Dwi Tunggal Pharma Mandiri Profile Updated: November 14, 2025
Buy our report for this company USD 29.95 Most recent financial data: 2025 Available in: English Download a sample report

Pt Dwi Tunggal Pharma Mandiri is based in Indonesia. The head office is in Medan. It operates in the Drugs and Druggists' Sundries Merchant Wholesalers sector. It was first established on January 12, 2004. The company’s latest financial report indicates a net sales revenue increase of 12.76% in 2025. Its’ total assets recorded a growth of 11.47%.

Headquarters
Jl. Letda Sujono Komplek Aksara Baru Blok G No. 316 Kelurahan Medan Estate, Kecamatan Percut Sei Tuan Medan 20226 Sumatera Utara - Indonesia
Medan; North Sumatra;

Contact Details: Purchase the Pt Dwi Tunggal Pharma Mandiri report to view the information.

Basic Information
Registered Capital:
Purchase the Pt Dwi Tunggal Pharma Mandiri report to view the information.
Financial Auditors:
Purchase the Pt Dwi Tunggal Pharma Mandiri report to view the information.
Incorporation Date:
January 12, 2004
Key Executives
Purchase this report to view the information.
Director
Purchase this report to view the information.
Commissioner
Ownership Details
Purchase this report to view the information.
Purchase this report to view the information.
Company Performance
Financial values in the chart are available after Pt Dwi Tunggal Pharma Mandiri report is purchased.
Looking for more than just a company report?

EMIS company profiles are part of a larger information service which combines company, industry and country data and analysis for over 145 emerging markets.

Request a demo of the EMIS service
Key Financial Highlights
Annual growth percentages for latest two years in local currency IDR. Absolute financial data is included in the purchased report.
Net sales revenue
12.76%▲
Total Operating Revenue
12.76%▲
Total Assets
11.47%▲

To view more information, Request a demonstration of the EMIS service

Buy this company report
Need ongoing access to company, industry or country information?